Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #1824 on Enanta Pharmaceuticals Inc (ENTA)
DewDiligence
01/09/20 10:48 AM
#1830 RE: DewDiligence #1824
• RSV N-inhibitor EDP-938 and hMPV Inhibitor Leads --Data from RSVP Phase 2b adult outpatient study in 3Q 2020 (if enrollment can be completed in one RSV season in northern hemisphere); --Initiate Phase 2 dose ranging study in pediatric RSV patients in 4Q 2020; --Initiate Phase 2 study in adult transplant patients with RSV in 4Q 2020; --Perform optimization of Enanta’s current nanomolar hMPV inhibitor leads. • HBV Core Inhibitor EDP-514 --Phase 1 data in healthy volunteers in 1Q 2020; --Initiate Phase 1b in nuc-suppressed HBV patients in 1Q 2020; --Initiate Phase 1b in viremic HBV patients in 2Q 2020. • NASH / PBC FXR Agonists EDP-305 and EDP-297 --Initiate ARGON-2 Phase 2b study of EDP-305 in NASH by early 2Q 2020; --Phase 2 data from INTREPID study of EDP-305 in PBC in 2Q 2020; --Initiate Phase 1 study of EDP-297 (follow-on FXR) in mid-2020; --Advance discovery of non-FXR compounds for NASH.